{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:00:39Z","timestamp":1778598039510,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"The Icelandic Center for Research"},{"name":"University of Iceland and Scientific and Technological Research Equipment Center"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ijpharm.2016.04.071","type":"journal-article","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T05:18:00Z","timestamp":1462079880000},"page":"21-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cyclodextrin-based telmisartan ophthalmic suspension: Formulation development for water-insoluble drugs"],"prefix":"10.1016","volume":"507","author":[{"given":"Chutimon","family":"Muankaew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phatsawee","family":"Jansook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e1kon Hrafn","family":"Sigur\u0111sson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsteinn","family":"Loftsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2016.04.071_bib0005","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1039\/C2CE26490K","article-title":"Quantitative analysis of the inhibitory effect of HPMC on felodipine crystallization kinetics using population balance modeling","volume":"15","author":"Abbou Oucherif","year":"2013","journal-title":"CrystEngComm"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejpb.2006.01.015","article-title":"Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage","volume":"63","author":"Abdelwahed","year":"2006","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0015","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jpba.2010.09.027","article-title":"Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state","volume":"54","author":"Al Omari","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0375-9601(73)90543-4","article-title":"Application of Ostwald's rule to amorphous materials","volume":"43","author":"Anseau","year":"1973","journal-title":"Phys. Lett. A"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0025","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1021\/jo0262154","article-title":"1H NMR studies of maltose, maltoheptaose, \u03b1-, \u03b2-, and \u03b3-cyclodextrins, and complexes in aqueous solutions with hydroxy protons as structural probes","volume":"68","author":"Bekiroglu","year":"2003","journal-title":"The Journal of Organic Chemistry"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejpb.2014.01.001","article-title":"Property profiling of biosimilar mucus in a novel mucus-containing in vitro model for assessment of intestinal drug absorption","volume":"87","author":"Boegh","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0035","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.carbpol.2015.06.098","article-title":"The effect of mechanical grinding on the formation, crystalline changes and dissolution behaviour of the inclusion complex of telmisartan and \u03b2-cyclodextrins","volume":"133","author":"Borba","year":"2015","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0040","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0045","first-page":"217","article-title":"Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions","volume":"63","author":"Brewster","year":"2008","journal-title":"Die Pharmazie \u2013 Int. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijpharm.2013.05.061","article-title":"Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery","volume":"453","author":"Brough","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/ja9828657","article-title":"Interconnective host\u2013guest complexation of \u00fc-cyclodextrin\u2212calix[4]arene couples","volume":"121","author":"B\u00fcgler","year":"1999","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0060","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ejps.2013.05.003","article-title":"Investigation and correlation of physical stability, dissolution behaviour and interaction parameter of amorphous solid dispersions of telmisartan: a drug development perspective","volume":"49","author":"Dukeck","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0065","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/adma.201201800","article-title":"Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery","volume":"24","author":"Ensign","year":"2012","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0070","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.drudis.2012.10.005","article-title":"Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers","volume":"18","author":"Gan","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.molstruc.2015.02.017","article-title":"Antipyrine\u2013gamma cyclodextrin inclusion complex: molecular modeling, preparation, characterization and cytotoxicity studies","volume":"1089","author":"Gannimani","year":"2015","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2013.06.036","article-title":"Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models","volume":"172","author":"Godugu","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0085","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/jps.22498","article-title":"Effect of cyclodextrin derivation and amorphous state of complex on accelerated degradation of ziprasidone","volume":"100","author":"Hong","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0090","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/aos.12334","article-title":"Kinetics of \u03b3-cyclodextrin nanoparticle suspension eye drops in tear fluid","volume":"92","author":"J\u00f3hannesson","year":"2014","journal-title":"Acta Ophthalmol. (Copenh.)"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0095","first-page":"1","article-title":"Cyclodextrin-poloxamer aggregates as nanocarriers in eye drop formulations: dexamethasone and amphotericin B","author":"Jansook","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000434693","article-title":"Microspheres and nanotechnology for drug delivery","volume":"55","author":"Johannesson","year":"2016","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0105","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.carbpol.2013.09.077","article-title":"Telmisartan complex augments solubility, dissolution and drug delivery in prostate cancer cells","volume":"101","author":"Kaur","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0110","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejpb.2008.05.023","article-title":"Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine","volume":"70","author":"Konno","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejps.2013.02.017","article-title":"Differential surface properties of commercial crystalline telmisartan samples","volume":"49","author":"Laad","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1350-9462(97)00002-5","article-title":"Ophthalmic drug delivery systems-Recent advances","volume":"17","author":"Le Bourlais","year":"1998","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0125","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1021\/la0523661","article-title":"Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening","volume":"22","author":"Lindfors","year":"2006","journal-title":"Langmuir"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0130","first-page":"3019","article-title":"Cyclodextrins as functional excipients: methods to enhance complexation efficiency","volume":"101","author":"Loftsson","year":"2012","journal-title":"Jun"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0135","series-title":"Drug Solubilization and Stabilization by Cyclodextrin Drug Carriers","first-page":"67","author":"Loftsson","year":"2013"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","article-title":"Cyclodextrins and their pharmaceutical applications","volume":"329","author":"Loftsson","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0145","first-page":"25","article-title":"Preparation of solid drug\/cyclodextrin complexes of acidic and basic drugs","volume":"59","author":"Loftsson","year":"2004","journal-title":"Die Pharmazie \u2013 Int. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijpharm.2005.05.042","article-title":"Evaluation of cyclodextrin solubilization of drugs","volume":"302","author":"Loftsson","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0155","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijpharm.2005.05.042","article-title":"Evaluation of cyclodextrin solubilization of drugs","volume":"302","author":"Loftsson","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0160","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10847-006-9247-2","article-title":"The complexation efficiency","volume":"57","author":"Loftsson","year":"2007","journal-title":"J. Inclusion Phenom. Macrocyclic Chem."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0165","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1211\/jpp.59.5.0002","article-title":"Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops","volume":"59","author":"Loftsson","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0170","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/jps.20992","article-title":"Effects of cyclodextrins on drug delivery through biological membranes","volume":"96","author":"Loftsson","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0175","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/jps.20992","article-title":"Effects of cyclodextrins on drug delivery through biological membranes","volume":"96","author":"Loftsson","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0180","first-page":"171","article-title":"Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations","volume":"63","author":"Loftsson","year":"2008","journal-title":"Pharmazie"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0185","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1208\/s12249-008-9055-7","article-title":"Carvedilol: solubilization and cyclodextrin complexation: a technical note","volume":"9","author":"Loftsson","year":"2008","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0190","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ijpharm.2012.11.012","article-title":"Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique","volume":"441","author":"Marasini","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0195","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1021\/cg7007599","article-title":"Hydroxypropyl methylcellulose-controlled crystallization of erythromycin a dihydrate crystals with modified morphology","volume":"8","author":"Mirza","year":"2008","journal-title":"Cryst. Growth Des."},{"issue":"Suppl. 1","key":"10.1016\/j.ijpharm.2016.04.071_bib0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.yrtph.2004.05.008","article-title":"Safety assessment of \u03b3-cyclodextrin","volume":"39","author":"Munro","year":"2004","journal-title":"Regul. Toxicol. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0205","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ejpb.2011.12.001","article-title":"Competitive displacement of drugs from cyclodextrin inclusion complex by polypseudorotaxane formation with poloxamer: implications in drug solubilization and delivery","volume":"80","author":"Nogueiras-Nieto","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0210","first-page":"64","article-title":"Lysis of human red blood cells in the presence of various cosolvents","volume":"39","author":"Reed","year":"1985","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0215","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijpharm.2012.08.034","article-title":"Amorphous ternary cyclodextrin nanocomposites of telmisartan for oral drug delivery: improved solubility and reduced pharmacokinetic variability","volume":"453","author":"Sangwai","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0220","series-title":"Sulfoalkyl Ether Cyclodextrin Based Controlled-release Solid Pharmaceutical Formulations","first-page":"59","author":"Stella","year":"2000"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0225","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jconrel.2008.04.001","article-title":"Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release","volume":"129","author":"Tran","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0230","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1248\/cpb.52.900","article-title":"Design and evaluation of cyclodextrin-Based drug formulation","volume":"52","author":"Uekama","year":"2004","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0235","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Del. Rev."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0240","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1167\/iovs.07-0964","article-title":"Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor","volume":"49","author":"Usui","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0245","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijpharm.2007.05.006","article-title":"Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design","volume":"342","author":"Vandecruys","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0250","first-page":"127","article-title":"A review on telmisartan: a novel, long-Acting angiotensin II-Receptor antagonist. cardiovasc","volume":"18","author":"Wienen","year":"2000","journal-title":"Drug Rev."},{"key":"10.1016\/j.ijpharm.2016.04.071_bib0255","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jpba.2014.03.019","article-title":"Enhancement of carvedilol solubility by solid dispersion technique using cyclodextrins, water soluble polymers and hydroxyl acid","volume":"96","author":"Yuvaraja","year":"2014","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316303635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316303635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T02:41:01Z","timestamp":1572576061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517316303635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":51,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0378517316303635"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.04.071","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclodextrin-based telmisartan ophthalmic suspension: Formulation development for water-insoluble drugs","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.04.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}